Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, has added a non-invasive genomic sequencing panel, Tempus xF, a liquid biopsy cell-free DNA assay that analyzes 77 genes, to its sequencing capabilities.. Tempus xF will be run in the company’s state-of-the-art next-generation seq...
Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today it has secured an additional $110 million in financing at a valuation of $2 billion dollars. The round includes Baillie Gifford, funds and accounts managed by T. Rowe Price, Revo...
CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), has brought on technology collaborators Concerto HealthAI and Tempus to accelerate its joint research effort with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) aimed at understanding the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors. Concerto HealthAI and Tempus have begun to assist in the analysis of a de-identified data set that CancerLinQ has provided to the...
Having met rigorous qualifications, Tempus joins a select group of commercial and academic laboratories designated to cast a wider net for patients to enter the trial Tempus announced today that it is participating as a CLIA-certified/accredited laboratory for the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY1...
Tempus today announced a new initiative that will allow physicians to sequence a second patient sample without additional charge, removing a barrier that oftentimes stands in the way of a patient being sequenced. The Tempus xT panel analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of...
Tempus announced today it has raised an additional $80M in financing. The round included existing investors, New Enterprise Associates and Revolution Growth, along with new investors Kinship Trust Company and funds advised by T. Rowe Price Associates, Inc. The additional funds will be used to further grow and...
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, has launched a new genomic sequencing panel, Tempus xE, which analyzes the whole exome in a CLIA/CAP validated assay. Tempus xE, unlike most commercial panels,...
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Parker Institute for Cancer Immunotherapy will work together to analyze clinical and molecular data to better determine which patients will have a positive response...
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced a collaboration with NYU School of Medicine aimed at improving outcomes for patients diagnosed with pancreatic cancer. Pancreatic cancer is the third leading cause...
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients. As part of the initial research project, Tempus will use...